Physician profile
Linxia Dong
NPI 1689915894
$13,020.46
in general payments reported to CMS, 2019-2025
41 companies · $2,861 in 2025
The $2,861 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,802 · 2022: $3,067 · 2023: $2,283 · 2024: $2,007 · 2025: $2,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,151.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,046.26 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $1,352.09 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $1,214.93 | 2021-2025 | Jardiance, Mounjaro, Lyumjev |
| Amgen INC. | $794.79 | 2021-2025 | Evenity, Prolia, Tepezza |
| Astrazeneca Pharmaceuticals Lp | $760.81 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $637.64 | 2021-2025 | Jardiance, Tradjenta |
| Xeris Pharmaceuticals, INC. | $601.64 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $598.88 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $555.18 | 2021-2023 | |
| Insulet Corporation | $377.76 | 2021-2025 | Omnipod |
| Abbvie INC. | $343.59 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $282.41 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $244.80 | 2022-2025 | Strensiq |
| Tandem Diabetes Care, INC. | $191.26 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $178.17 | 2023-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $170.43 | 2021-2022 | |
| Corcept Therapeutics | $168.61 | 2024-2025 | Korlym |
| Medtronic, INC. | $163.02 | 2023-2025 | Minimed 780g, Minimed 770g |
| Mannkind Corporation | $146.10 | 2022 | |
| Recordati_rare_diseases_inc. | $143.06 | 2022-2025 | Isturisa, Signifor Lar |
| Amarin Pharma, INC. | $140.81 | 2021 | |
| Ibsa Pharma INC. | $137.41 | 2021-2024 | Licart, Tirosint, Tirosint |
| Merck Sharp & Dohme LLC | $118.70 | 2021 | |
| Pfizer INC. | $86.62 | 2022-2025 | |
| Ascendis Pharma Endocrinology INC | $74.31 | 2025 | Yorvipath |
| Rhythm Pharmaceuticals, INC. | $56.12 | 2025 | Imcivree |
| Cequr Corporation | $44.06 | 2023-2025 | Cequr Simplicity |
| Madrigal Pharmaceuticals | $42.14 | 2025 | Rezdiffra |
| Ultragenyx Pharmaceutical INC. | $40.52 | 2022-2024 | Crysvita |
| Esperion Therapeutics, INC. | $38.62 | 2021 | |
| Sequel Med Tech, LLC | $38.21 | 2025 | Twiist |
| Eusa Pharma (US) LLC | $35.08 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $29.87 | 2023 | Inpefa |
| Amryt Pharma Holdings Ltd | $25.09 | 2022 | |
| Amneal Pharmaceuticals LLC | $23.83 | 2024 | Unithroid |
| Alvogen INC | $23.13 | 2025 | Teriparatide |
| Neurocrine Biosciences, INC. | $21.45 | 2025 | |
| Becton, Dickinson and Company | $18.93 | 2022 | |
| Glaxosmithkline, LLC. | $18.76 | 2025 | Shingrix |
| Ipsen Biopharmaceuticals, INC | $18.14 | 2022 | |
| Kyowa Kirin, INC. | $17.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linxia Dong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.